The Withdrawal
Oxbryta (voxelotor) was a Pfizer medication approved to treat sickle cell disease, a serious inherited blood disorder, by helping keep red blood cells from sickling. In September 2024, Pfizer voluntarily withdrew Oxbryta from markets worldwide and halted its clinical trials and expanded-access programs. The reason was sobering: an analysis of the accumulated data suggested an imbalance in vaso-occlusive crises — the intensely painful episodes that define sickle cell disease — and in fatal events among patients taking the drug, leading Pfizer to conclude the overall benefit no longer clearly outweighed the risk.
It is worth being careful and fair here: sickle cell disease is itself dangerous, the withdrawal was precautionary, and researchers were still assessing the data when the drug was pulled.
The Emerging Litigation
Following the withdrawal, lawsuits began to be filed by patients and families alleging that Oxbryta caused harm — including wrongful-death claims tied to strokes or pain crises — and that the risks were not adequately conveyed. This litigation is at an early, emerging stage; there is no large consolidated proceeding or broad settlement, though at least one wrongful-death matter has reportedly been resolved in principle. As with any drug case, a central and difficult question will be whether an individual’s injury or death was caused by the medication or by the underlying disease.
Because sickle cell disease independently causes crises and strokes, tying a specific outcome to the drug is genuinely complex.
What Patients Should Know
If you or a family member took Oxbryta, do not make treatment changes without a doctor — sickle cell disease requires careful management, and your care team can discuss alternatives. Keep medical records documenting the treatment and any complications. Given how new and uncertain this litigation is, be wary of advertising that presents outcomes as certain, and prioritize medical guidance over legal marketing.
Before You Act
Thinking About Filing a Claim?
Most plaintiff lawyers offer a free initial consultation and work on contingency, meaning no fee unless there is a recovery. LawsuitWatch is not a law firm: we publish explainers, and we do not provide legal advice, representation or referrals. Your state bar directory is the reliable place to find and verify a lawyer.
Oxbryta Recall Lawsuit: The Withdrawn Sickle-Cell Drug: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
Why was Oxbryta withdrawn?
In September 2024 Pfizer voluntarily withdrew Oxbryta (voxelotor) worldwide after accumulated data suggested an imbalance in painful vaso-occlusive crises and in fatal events among patients, leading Pfizer to conclude the benefit no longer clearly outweighed the risk. The withdrawal was precautionary.
Is there an Oxbryta lawsuit settlement?
The litigation is early and emerging, with no large consolidated proceeding or broad settlement, though at least one wrongful-death matter has reportedly been resolved in principle.
What should Oxbryta patients do?
Do not change treatment without your doctor — sickle cell disease needs careful management and alternatives can be discussed. Keep medical records, and be cautious of advertising that presents legal outcomes as certain.
Legal Disclaimer
This article is general legal information, not legal advice, and does not create an attorney-client relationship. Case status, eligibility criteria, and any amounts described are as reported at the date shown and may change. Consult a licensed attorney in your jurisdiction about your own situation.